In the business of clinical trials, the most valuable
commodities are the research subjects.
Filling clinical trials is hard, and filling them quickly is even
harder. That’s why in 2000 a clinical investigator told the HHS Office of the
Inspector General that research sponsors were looking for three things from
research sites: “No. 1—rapid enrollment. No.
2 — rapid enrollment. No. 3 — rapid
enrollment.”
Back in the early 2000s, the University of Minnesota’s Department
of Psychiatry was having so much trouble getting research subjects that
Quintiles, a Contract Research Organization, had put it on probation. Perhaps the department’s difficulty convincing
subjects to sign up for trials should not have been a surprise, given its alarming history
of research scandals. Yet by December
2003, the Department had managed a 180-degree turn. In fact, it had become so successful in getting
subjects into trials that Quintiles had profiled it in a CAFÉ study
webcast. How did the Department manage
to become such an aggressively successful recruiting site?
A hint emerges in this
document from the lawsuit against the University of Minnesota brought by
Mary Weiss over the suicide of her son, Dan Markingson. The document, dated April 14, 2003, is labeled
“CAFÉ Study Coordinator Teleconference,” and it mentions a number of strategies
for recruiting subjects.
First, the document references a discussion of “ways to utilize
subjects for multiple studies.” The phrase
“multiple studies” should set off a red flag.
Enrolling severely mentally ill subjects in multiple industry-funded studies
was exactly the strategy of former University of Minnesota psychiatrist Faruk
Abuzzahab, who was eventually found to be responsible for the deaths
and injuries of 46 patients.
Second, the document discusses a “newly-added 16 bed
psychosis specialty unit” where all nurses and staff are “supportive of
research” and “all patients are reviewed for possible research candidacy.” Every patient? Remember, patients with psychotic illnesses are
among the most vulnerable patients in the hospital. Because of their thought disorders, they are
often unable to understand and appreciate the risks of research. Yet according to this document, every patient
on the psychosis unit is evaluated for his or her suitability for research
studies -- and perhaps even multiple studies.
How exactly do the Minnesota psychiatrists accomplish this?
Apparently one way is to have research staff “attend morning
report before inpatient rounds take place,” in order to “identify any possible
subjects who might be eligible for studies.” Yet again, this statement should raise alarm bells. Morning report is a time for discussing the
care of patients, where private medical information is revealed. Why should research staff working for pharmaceutical
companies and Contract Research Organizations be given privileged access to the
private health information of hospitalized patients? Of course, privacy violations were at the
heart of Mike Howard’s complaint about Stephen Olson to the Board of Regents,
which was dismissed
by the General Counsel.
This is an alarming document, but even more alarming is the
fact that nobody at the University of Minnesota is willing to look into the
issues it raises – not the Board of Regents, not the Research Subject Advocate,
not the Research Integrity Officer, and not the Research Ethics Consultation
Service. At the very least someone
should be asking the question: how do we know that the suicide of Dan Markingson in the CAFÉ study
was an isolated case?
The only information missing here is the fact that this "specialty," locked unit within Fairview-Riverside Hospital is the brainchild of Charles Schulz, the chair of psychiatry who was recruited because of his reputation for amassing large amounts of pharmaceutical dollars, some of which was actually even deposited by the U, for all of his appearances on numerous speaker circuits disseminating all the newest and greatest drug data(well, actually a lot was old data just revisited with a new spin)
ReplyDeleteIt's not really science, but an opinion piece from someone with some vested interest. Typically Schulz’s articles are of good quality (mainly because they are never his original work) but, many of the references are review articles, not original studies, and rely heavily on their own previous review articles and on those of co-authors who clearly run in the same circles. Left on his own Schulz typically uses a tiny fraction of the literature to support an opinion (that the study drug doesn't do any harm) which is absolutely not supported by the weight of the available evidence. He also has an annoying habit of stating something non-controversial and referencing that extensively, then asserting something outrageous without any reference at all---the journal reviewers shouldn't let him get away with this, so this speaks to the quality of the journal, mainly the American Psychiatric Association's own publishing firm....which is funded by of course the pharmaceutical companies paying Chuck for selling their drugs.